Company · CIK 0001801198 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Legend Biotech Corp · LEGN
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 SForm 4 → | Sep 23, 4:15 pm EDT | Carlos E SantosChief Financial Officer | 5,430 | $9.14 | $49,630 | 14,246 | −27.6% | |
| Sep 21, 2026 AForm 4 → | Sep 23, 4:15 pm EDT | Carlos E SantosChief Financial Officer | 19,676 | — | — | 19,676 | — | |
| Sep 15, 2026 AForm 4 → | Sep 16, 4:18 pm EDT | Ingrid ZhangChief Executive Officer | 1,131,860 | — | — | 1,131,860 | — | |
| Aug 14, 2026 AForm 4 → | Aug 18, 4:15 pm EDT | Alan BashInterim CEO | 4,908 | — | — | 35,142 | — | |
| Jun 30, 2026 SForm 4 → | Jul 2, 4:05 pm EDT | Patrick John CaseyDirector | 6,000 | $14.80 | $88,800 | 48,604 | −11.0% | |
| Jun 30, 2026 GForm 4 → | Jul 2, 4:05 pm EDT | Ying HuangChief Executive Officer, Director | 3,382 | — | — | 238,490 | — | |
| Jun 25, 2026 SForm 4 → | Jun 29, 9:53 pm EDT | Ying HuangChief Executive Officer, Director | 5,566 | $14.78 | $82,265 | 241,872 | −2.25% |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.